Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Health

    Sinovac COVID-19 vaccine granted conditional market approval in China

    Xinhua | Updated: 2021-02-07 09:35
    Share
    Share - WeChat
    A staff member of Sinovac Biotech, a Chinese biopharmaceutical company, displays two doses of COVID-19 inactivated vaccine in prefilled syringes in Beijing, capital of China, Dec 23, 2020. [Photo/Xinhua]

    BEIJING -- China's National Medical Products Administration on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday.

    The Sinovac vaccine, produced by the Beijing-based Sinovac Life Sciences Co Ltd, affiliated with Sinovac Biotech, was approved for emergency use in China last June. The vaccine started being used for emergency inoculation among some special groups in the country from July last year.

    From this January, countries including Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay and Laos successively approved the emergency use of the Sinovac vaccine locally.

    These countries recognize the clinical research results of the vaccine, believing it has obvious effects on reducing the medical treatment, hospitalization, critical cases and deaths caused by COVID-19, and is of great importance to pandemic prevention and control, Sinovac Biotech said in a press release on its website.

    Sinovac Life Sciences Co Ltd on Feb 3 filed an application for conditional market approval of CoronaVac, which was granted on the basis of the vaccine's overseas phase-3 clinical trials for two months, it said.

    The NMPA requested the company to continue to carry out relevant clinical trials, fulfill the conditional requirements, and submit the follow-up research results in time.

    "We expect to provide more safe and effective vaccines as soon as possible and help control COVID-19 ultimately by increasing inoculation rates, enabling social and economic development to return to the normal track," said Yin Weidong, chairman and CEO of Sinovac.

    According to the company, the vaccination procedure includes two shots with an interval of 14 to 28 days, and each dose is 0.5 ml.

    In China, the vaccine has completed its phase-1 and phase-2 clinical trials for adults aged over 18 and the elderly, and the enrollment of volunteers aged 3 to 17 has been completed. The volunteers in China has reached more than 2,200 people and the results showed that the vaccine has good safety and immunogenicity in all age groups.

    Since July 2020, Sinovac has conducted phase-3 clinical trials in four countries including Brazil, Chile, Indonesia and Turkey, involving more than 25,000 volunteers altogether.

    As of December 16, 2020, 12,396 medical workers aged over 18 were enrolled in Brazil and 253 infection cases were collected during the observation period. Clinical studies in Brazil suggested that the vaccine was 100 percent effective in preventing hospitalized, severe, and fatal cases, 83.7 percent effective in preventing cases requiring medical treatment, and has a general efficacy rate of 50.65 percent.

    Clinical trials in Turkey involved both health care workers aged 18-59 who are at high risk and the general population at normal risk. Results in Turkey showed that the vaccine has an efficacy rate of 91.25 percent.

    The vaccine production quality management system has passed GMP inspections in many countries including China, Brazil, Indonesia and Chile. Hundreds of batches of large-scale production have proved that the vaccine production process is controllable and the quality is reliable.

    Sinovac's first production line which went into operation in August 2020 has an annual production capacity of 500 million doses. The company has constructed a second production line, which will start operation in February, increasing its annual production capacity to 1 billion doses.

    Sinovac will also export semi-finished jabs to some countries with filling and packaging capabilities such as Brazil, Indonesia and Turkey.

    The supply of vaccines in the form of both finished and semi-finished products will help fill the gap of the company's filling and packaging capacity, save the international transportation cost, and improve the accessibility and affordability of vaccines, the company said.

    It is China's second self-developed COVID-19 vaccine that has got conditional market approval in the country. The vaccine developed by China National Biotec Group affiliated with Sinopharm was approved in December last year.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    亚洲va无码va在线va天堂| 伊人久久无码中文字幕| 精品人妻中文av一区二区三区| 无套内射在线无码播放| 中文字幕免费观看| 亚洲国产91精品无码专区| 亚洲AV无码1区2区久久| 中文字幕1级在线| 久久中文字幕一区二区| 伊人久久大香线蕉无码麻豆| 久热中文字幕无码视频| 亚洲一区AV无码少妇电影☆| 欧美日韩亚洲中文字幕二区 | 久久久久亚洲AV无码观看| 色婷婷综合久久久中文字幕 | 中文字幕无码播放免费| 国产精品无码DVD在线观看| 中文字幕乱妇无码AV在线| √天堂中文www官网在线| 无码中文字幕日韩专区视频 | 日本中文字幕网站| 久久精品人妻中文系列| 亚欧无码精品无码有性视频| 国产网红主播无码精品| 国产精品无码一区二区在线观一| 老司机亚洲精品影院无码| 日韩av无码一区二区三区| 手机永久无码国产AV毛片| 亚洲av中文无码乱人伦在线咪咕 | 亚洲AV中文无码乱人伦在线视色| 中文字幕久精品免费视频| 亚洲欧美综合在线中文| 中文字幕乱码一区二区免费| 中文字幕亚洲欧美日韩在线不卡| 亚洲男人第一无码aⅴ网站| 一级毛片中出无码| 日韩精品无码中文字幕一区二区 | 最近中文字幕mv免费高清在线 | 久久久久久久久久久久中文字幕| 久久人妻无码中文字幕| 精品久久久久久中文字幕|